Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Not yet recruiting Phase 3 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability, and Immunogenicity of 3 Lots of a Multivalent Pneumococcal Conjugate Vaccine Administered to Adults

ClinicalTrials.gov ID: NCT07794748

Public ClinicalTrials.gov record NCT07794748. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 2:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF 3 LOTS OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to provide safety data and demonstrate lot consistency with the PG4 vaccine by evaluating the immunogenicity of 3 different lots of this vaccine. This study will compare a new pneumococcal vaccine with the vaccine currently in use to see if they are similarly safe. It will also compare three batches of the new vaccine to make sure they work the same way. Blood samples will be taken to measure how the body responds to the vaccines. The study will be conducted in the United States. Participants will be assigned to 1 of 4 groups. Group 1: PG4 vaccine lot 1; Group 2: PG4 vaccine lot 2; Group 3: PG4 vaccine lot 3; Group 4: 20vPnC. Within each group, participants will be assigned by chance in a 2:2:2:1 ratio to receive 1 vaccine injection (shot) with either PG4 (new vaccine) lot 1, PG4 lot 2, PG4 Lot 3 or 20vPnC, given in the arm. This means that for every 7 participants, about 2 will receive either PG4 lot 1, lot 2 or lot 3 and about 1 will receive 20vPnC. Each participant will take part in the study for approximately 6 months.

Study identification

NCT ID
NCT07794748
Recruitment status
Not yet recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Pfizer
Industry
Enrollment
4,670 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 49 Years
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 7, 2026
Primary completion
Jun 6, 2027
Completion
Jun 6, 2027
Last update posted
Aug 30, 2026

2026 – 2027

United States locations

U.S. sites
25
U.S. states
15
U.S. cities
23
Facility City State ZIP Site status
Orange County Research Center Lake Forest California 92630
Diablo Clinical Research, LLC dba Flourish Research Walnut Creek California 94598
Clinical Research Consulting Milford Connecticut 06460
Suncoast Research Associates Doral Florida 33172
Entrust Clinical Research Miami Florida 33176
Palm Springs Community Health Center Miami Lakes Florida 33014
Indago Research and Health Center, Inc. Miami Lakes Florida 33016
Palm Beach Research Center West Palm Beach Florida 33409
Javara Inc. Fayetteville Georgia 30214
Clinical Research Atlanta Stockbridge Georgia 30281
East-West Medical Research Institute Honolulu Hawaii 96814
DM Clinical Research Melrose Park Illinois 60160
Velocity Clinical Research, Sioux City Sioux City Iowa 51106
Henry Ford St. John Hospital - Thomas Mackey Center for Infectious Disease Research Grosse Pointe Woods Michigan 48236
Clinical Research Professionals Chesterfield Missouri 63005
Velocity Clinical Research, Grand Island Grand Island Nebraska 68803
Accellacare - Wilmington Wilmington North Carolina 28401
CTI Clinical Research Center Cincinnati Ohio 45212
Clinical Trials of South Carolina Moncks Corner South Carolina 29461
TMA Headlands LLC (d/b/a Trial Management Associates) Myrtle Beach South Carolina 29572
SMS Clinical Research LLC Mesquite Texas 75149
DM Clinical Research - Sugar Land Sugar Land Texas 77478
DM Clinical Research Tomball Texas 77375
J. Lewis Research, Inc. / Foothill Family Clinic Salt Lake City Utah 84109
J. Lewis Research, Inc. / Foothill Family Clinic South Salt Lake City Utah 84121

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07794748, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 30, 2026 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07794748 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →